Dotatate is a peptide–chelator molecule that targets somatostatin receptors, especially SSTR2. Its gallium-68 and copper-64 products are PET tracers. Lutetium-177 dotatate delivers therapeutic radiation to selected neuroendocrine tumors. PET maps tracer uptake; CT supplies anatomical detail.
Key takeaways
- Dotatate combines octreotate, a receptor-targeting peptide, with the DOTA chelator; the radioactive metal is added separately.
- Ga-68 and Cu-64 products support PET imaging. Lu-177 dotatate treats SSTR-positive gastroenteropancreatic neuroendocrine tumors in patients aged 12 and older.
- DOTATATE PET maps receptor-related tracer uptake, while CT shows anatomy. Receptor status shapes which tumors can be detected.
- NETTER-1 and NETTER-2 found longer progression-free survival with Lu-177 dotatate plus octreotide than with high-dose octreotide. NETTER-1’s final overall-survival result was not statistically significant.
- Imaging and treatment have different radiation and monitoring requirements; they are distinct prescription radiopharmaceuticals.
In this article
Dotatate is a peptide–chelator molecule that targets somatostatin receptors, especially SSTR2. Its gallium-68 and copper-64 products are PET tracers; lutetium-177 dotatate delivers therapeutic radiation. The same targeting approach supports both finding neuroendocrine tumors and treating selected receptor-positive disease.
What DOTATATE is
Dotatate combines octreotate, a somatostatin-like peptide, with DOTA, a molecule that binds a metal ion. Dotatate itself is this peptide–chelator conjugate; adding a particular radioactive metal creates the imaging or treatment product. The NETSPOT label describes a cyclic eight-amino-acid peptide linked to DOTA (NETSPOT prescribing information, sections 11–12).
Many neuroendocrine tumors express somatostatin receptors, including SSTR2. That gives the peptide a biological target. The radionuclide supplies the detectable signal or therapeutic radiation (DETECTNET prescribing information, section 12.1). This pairing of targeted imaging and treatment is called theranostics.
How DOTATATE PET/CT works
PET shows where the radioactive tracer accumulates. CT supplies the anatomical detail, allowing clinicians to locate that uptake in the body. PET therefore adds receptor-related information to structural imaging; it is more than a conventional X-ray.
SSTR expression matters: a tumor with little receptor expression may be difficult to see with this tracer. Uptake can also occur in normal organs and conditions such as inflammation. A PET finding needs interpretation alongside CT and the clinical picture (NETSPOT prescribing information, sections 2.7 and 5.3).
Ga-68 and Cu-64: two PET diagnostics
| Product | Radioactive metal | U.S. approved imaging population |
|---|---|---|
| NETSPOT | Gallium-68 | Adults and children with SSTR-positive neuroendocrine tumors |
| DETECTNET | Copper-64 | Adults with SSTR-positive neuroendocrine tumors |
Both are approved for PET localization of this receptor-defined tumor group. Their physical half-lives differ: approximately 68 minutes for gallium-68 and 12.7 hours for copper-64. The longer copper-64 half-life affects production, transport, and scheduling; it does not by itself establish a superior scan (NETSPOT label; DETECTNET label).
From imaging to therapy: Lu-177 DOTATATE
Lutetium-177 dotatate, sold as LUTATHERA, uses receptor binding to deliver beta radiation. After binding and internalization, the emitted radiation can damage the targeted cell and nearby cells (LUTATHERA prescribing information, section 12.1).
Its U.S. indication covers SSTR-positive gastroenteropancreatic neuroendocrine tumors in adults and children aged 12 and older. Gastroenteropancreatic describes tumors of the gastrointestinal tract and pancreas. This is a specific tumor and receptor population, rather than cancer in general (National Cancer Institute).
What NETTER-1 and NETTER-2 showed
These randomized phase III studies asked different questions. NETTER-1 enrolled adults with progressive, well-differentiated midgut tumors. NETTER-2 enrolled patients with newly diagnosed, advanced, higher-grade gastroenteropancreatic tumors. Both required SSTR-positive disease and compared lutetium-177 dotatate plus long-acting octreotide with high-dose long-acting octreotide.
| Finding | NETTER-1 | NETTER-2 |
|---|---|---|
| Population | Adults with midgut NETs progressing on octreotide; Ki67 20% or less | Age 15+; advanced, well-differentiated GEP-NETs; Ki67 10%–55% |
| Randomized in the initial publication | 229: 116 versus 113 | 226: 151 versus 75 |
| Median progression-free survival | Not reached versus 8.4 months | 22.8 versus 8.5 months |
| Hazard ratio for progression or death | 0.21 (95% CI 0.13–0.33) | 0.276 (95% CI 0.182–0.418) |
| Overall-survival result | Final median 48.0 versus 36.3 months; P=0.30 | Primary report focused on progression-free survival |
Sources: NETTER-1 initial report, NEJM 2017, NETTER-1 final report, Lancet Oncology 2021, and NETTER-2, Lancet 2024.
Progression-free survival (PFS) measures time until disease progression or death. Both trials favored the lutetium-177 treatment for this endpoint. Their comparator was high-dose octreotide; these results do not rank every available treatment.
The NETTER-1 initial publication reported 229 randomized patients; its later final report described 231. The PFS row uses the initial report, including its 8.4-month control median. The final overall-survival difference was not statistically significant (HR 0.84; 95% CI 0.60–1.17). The two reports and endpoints should remain distinct.
NETTER-2 studied grade 2 tumors with Ki67 10%–20% and grade 3 tumors above 20% through 55%. Its PFS result supports treatment in that studied population; it is not a cure rate or an established overall-survival benefit. Both trials were funded by Advanced Accelerator Applications, a Novartis company.
Safety and monitoring
The imaging products expose patients to ionizing radiation and carry warnings about hypersensitivity and image misinterpretation (NETSPOT label; DETECTNET label).
LUTATHERA requires monitoring for blood-cell suppression and kidney and liver toxicity, among other labeled risks. Its warnings include later myelodysplastic syndrome or leukemia, hormonal crisis, reproductive harm, and radiation exposure (LUTATHERA prescribing information, section 5). In NETTER-1's final analysis, two of 111 treated patients developed myelodysplastic syndrome (final trial report).
In NETTER-2, any-grade adverse events during treatment occurred in 136 of 147 treated patients in the lutetium-177 group and 69 of 73 in the control group. The paper reported no study-drug-related deaths during that period (NETTER-2 primary report). Those safety denominators differ from the numbers randomized.
Frequently asked questions
What is the difference between Ga-68, Cu-64, and Lu-177 DOTATATE?
Gallium-68 and copper-64 dotatate are PET imaging agents. Lutetium-177 dotatate delivers beta radiation for treatment. All use the same receptor-targeting approach, but each is a distinct radiopharmaceutical product.
Which tumors can DOTATATE imaging detect?
Its approved imaging use is localization of somatostatin receptor-positive neuroendocrine tumors. Uptake depends on receptor expression and also occurs in some normal tissues and other conditions, so clinicians interpret PET together with anatomy and other findings.
This article explains clinical research and prescription radiopharmaceuticals. It is general information, not individual medical advice.
Sources
- NETSPOT prescribing information: DailyMed record updated July 6, 2026; prescribing information revised October 2023
- DETECTNET prescribing information
- LUTATHERA prescribing information
- National Cancer Institute: Lutetium Lu 177-Dotatate
- Strosberg et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. NEJM, 2017
- Strosberg et al. NETTER-1 final overall survival and long-term safety. Lancet Oncology, 2021
- Singh et al. NETTER-2. Lancet, 2024